Physicochemical characterization, solubilization, and stabilization of 9-Nitrocamptothecin using pluronic block copolymers

Journal of Pharmaceutical Sciences

Volumn 102, Issue 10, 2013, Pages 3653-3665

  Saha, Sohodeb C ^a,b   Patel, Deval ^a   Rahman, Shahidur ^a   Savva, Michalakis ^a,c  

^a LONG ISLAND UNIVERSITY   (United States)

^b Teva Pharmaceuticals   (United States)

^c NONE   (Cyprus)

Author keywords

9 nitrocamptothecin; Hydrolysis; Kinetics; Micelles; N oxide; Physicochemical properties; Pluronic; Preformulation; Solubility; Stability

Indexed keywords

CARBOXYLIC ACID; LACTONE; POLOXAMER; RUBITECAN;

ARTICLE; DRUG DELIVERY SYSTEM; HYDROLYSIS; MELTING POINT; MICELLE; OXIDATION; PH; PHYSICAL CHEMISTRY; SOLUBILITY;

9-NITROCAMPTOTHECIN; HYDROLYSIS; KINETICS; MICELLES; N-OXIDE; PHYSICOCHEMICAL PROPERTIES; PLURONIC; PREFORMULATION; SOLUBILITY; STABILITY;

CAMPTOTHECIN; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; LACTONES; MICELLES; OXIDATION-REDUCTION; POLOXAMER; POLYMERS; SOLUBILITY; TEMPERATURE; THERMODYNAMICS; WATER;

EID: 84883797958     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23671     Document Type: Article

References (72)

1. Derakhshandeh K, Soheili M, Dadashzadeh S, Saghiri R. 2010. Preparation and in vitro characterization of 9-nitrocamptothecin-loaded long circulating nanoparticles for delivery in cancer patients. Int J Nanomedicine 5:463-471.
2. Tong R, Cheng J. 2010. Controlled synthesis of camptothecin-polylactide conjugates and nanoconjugates. Bioconjug Chem 21:111-121.
3. Baranello L, Bertozzi D, Fogli MV, Pommier Y, Capranico G. 2010. DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1alpha gene locus. Nucleic Acids Res 38:159-171.
4. Li Q, Lv H, Zu Y, Qu Z, Yao L, Su L, Liu C, Wang L. 2009. Synthesis and antitumor activity of novel 20s-camptothecin analogues. Bioorg Med Chem Lett 19:513-515.
5. Teicher BA. 2008. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 75:1262-1271.
6. Sirikantaramas S, Asano T, Sudo H, Yamazaki M, Saito K. 2007. Camptothecin: Therapeutic potential and biotechnology. Curr Pharm Biotechnol 8:196-202.
7. Thomas CJ, Rahier NJ, Hecht SM. 2004. Camptothecin: Current perspectives. Bioorg Med Chem 12:1585-1604.
8. Koshkina NV, Waldrep JC, Knight V. 2003. Camptothecins and lung cancer: Improved delivery systems by aerosol. Curr Cancer Drug Targets 3:251-264.
9. Giovanella BC, Stehlin JS, Hinz HR, Kozielski AJ, Harris NJ, Vardeman DM. 2002. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan). Int J Oncol 20:81-88.
10. Garcia-Carbonero R, Supko JG. 2002. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641-661.
11. Chourpa I, Riou JF, Millot JM, Pommier Y, Manfait M. 1998. Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA. Biochemistry 37:7284-7291.
12. Ulukan H, Swaan PW. 2002. Camptothecins: A review of their chemotherapeutic potential. Drugs 62:2039-2057.
13. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. 1970. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461-470.
14. Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK, Hertzberg RP. 1991. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 34:98-107.
15. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. 1991. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191.
16. Oostendorp RL, Loftiss J, Goel S, Smith DA, Dar MM, Witteveen PO, Cohen RB, Lewis LD, Kurian S, Patnaik A, Rosing H, Beijnen JH, Voest EE, Burris HJ. 2009. Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors. Int J Clin Pharmacol Ther 47:195-206.
17. Ratain MJ, Innocenti F. 2010. Individualizing dosing of irinotecan. Clin Cancer Res 16:371-372.
18. Pantazis P, Early JA, Kozielski AJ, Mendoza JT, Hinz HR, Giovanella BC. 1993. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: Differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res 53:1577-1582.
19. Giovanella BC, Stehlin JS, Hinz HR, Kozielski AJ, Harris NJ, Vardeman DM. 2002. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan). Int J Oncol 20:81-88.
20. Pantazis P, Kozielski A, Rodriguez R, Petry E, Wani M, Wall M, Giovanella B. 1994. Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts. Melanoma Res 4:5-10.
21. Verschraegen CF, Natelson EA, Giovanella BC, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Ende K, Stehlin JS. 1998. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 9:36-44.
22. Konstadoulakis MM, Antonakis PT, Tsibloulis BG, Stathopoulos GP, Manouras AP, Mylonaki DB, Golematis BX. 2001. A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 48:417-420.
23. Ellerhorst JA, Bedikian AY, Smith TM, Papadopoulos NE, Plager C, Eton O. 2002. Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. Anticancer Drugs 13:169-172.
24. Adis International Limited. 2004. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000. Drugs R D 5:305-311.
25. Kepler JA, Wani MC, McNaull JN, Wall ME, Levine SG. 1969. Plant antitumor agents. IV. An approach toward the synthesis of camptothecin. J Org Chem 34:3853-3858.
26. Hsiang YH, Hertzberg R, Hecht S, Liu LF. 1985. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878.
27. Hsiang YH, Lihou MG, Liu LF. 1989. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082.
28. Hertzberg RP, Caranfa MJ, Hecht SM. 1989. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28:4629-4638.
29. Bjornsti MA, Benedetti P, Viglianti GA, Wang JC. 1989. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 49:6318-6323.
30. Gottlieb JA, Luce JK. 1972. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56:103-105.
31. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. 1972. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95-101.
32. Mi Z, Burke TG. 1994. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33:10325-10336.
33. Burke TG, Mi Z. 1994. The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability. J Med Chem 37:40-46.
34. Burke TG, Mi Z. 1993. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 212:285-287.
35. Tanford C. 1980. The Hydrophobic effect: Formation of micelles and biological membranes. New York: Wiley.
36. Allen C, Maysinge D, Eisenberg A. 1999. Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf B Biointerfaces 16:3-27.
37. Nagarajan R, Ganesh K. 1989. Block copolymer self-assembly in selective solvents: Spherical micelles with segregated cores. J Chem Phys 90:5843-5856.
38. Bromberg L. 2008. Polymeric micelles in oral chemotherapy. J Control Release 128:99-112.
39. Zhang W, Shi Y, Chen Y, Yu S, Hao J, Luo J, Sha X, Fang X. 2010. Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur J Pharm Biopharm 75:341-353.
40. Sawant RR, Sawant RM, Torchilin VP. 2008. Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: Improved drug solubilization and enhanced in vitro cytotoxicity. Eur J Pharm Biopharm 70:51-57.
41. Gao Y, Li LB, Zhai G. 2008. Preparation and characterization of pluronic/TPGS mixed micelles for solubilization of camptothecin. Colloids Surf B Biointerfaces 64:194-199.
42. Jones M, Leroux J. 1999. Polymeric micelles-A new generation of colloidal drug carriers. Eur J Pharm Biopharm 48:101-111.
43. Kabanov AV, Batrakova EV, Alakhov VY. 2002. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 82:189-212.
44. Musacchio T, Torchilin VP. 2011. Recent developments in lipid-based pharmaceutical nanocarriers. Front Biosci 16:1388-1412.
45. Gao J, Ming J, He B, Fan Y, Gu Z, Zhang X. 2008. Preparation and characterization of novel polymeric micelles for 9-nitro-20(S)-camptothecin delivery. Eur J Pharm Sci. 34:85-93.
46. Kawano K, Watanabe M, Yamamoto T, Yokoyama M, Opanasopit P, Okano T, Maitani Y. 2006. Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J Control Release 112:329-332.
47. Kunadharaju S, Savva M. 2008. Kinetic and thermodynamic analysis of 10-hydroxy-camptothecin hydrolysis at physiological pH. J Chem Thermodyn 40:1439-1444.
48. Thakur R, Kunadharaju S, Savva M. 2009. Kinetic and thermodynamic characterization of camptothecin hydrolysis at physiological pH in the absence and presence of human serum albumin. Int J Chem Kinet 41:704-715.
49. Saha SC, Kunadharaju S, Sivakumar B, Savva M. 2010. Kinetic and thermodynamic analysis of 9-nitro-camptothecin at physiological pH in the presence and absence of human serum albumin. Int J Chem Kinet 42:693-703.
50. Maurice-Estepa L, Levillain P, Lacour B, Daudon M. 2000. Advantage of zero-crossing-point first-derivative spectrophotometry for the quantification of calcium oxalate crystalline phases by infrared spectrophotometry. Clin Chim Acta 298:1-11.
51. Prasad CV, Parihar C, Sunil K, Parimoo P. 1998. Simultaneous determination of amiloride HCl, hydrochlorothiazide and atenolol in combined formulations by derivative spectroscopy. J Pharm Biomed Anal 17:877-884.
52. Taulier A, Levillain P, Lemonnier A. 1987. Determining methemoglobin in blood by zero-crossing-point first-derivative spectrophotometry. Clin Chem 33:1767-1770.
53. Kunadharaju S, Savva M. 2010. Thermodynamic studies of 10-hydroxy-camptothecin in aqueous solutions. J Chem Eng Data 55:103-112.
54. Thakur R, Sivakumar B, Savva M. 2010. Thermodynamic studies and loading of 7-ethyl-10-hydroxycamptothecin into mesoporous silica particles MCM-41 in strongly acidic solutions. J Phys Chem B 114:5903-5911.
55. Engelmann FM, Rocha SV, Toma HE, Araki K, Baptista MS. 2007. Determination of n-octanol/water partition and membrane binding of cationic porphyrins. Int J Pharm 329:12-18.
56. Paschke A, Neitze PL, Neitze W, Schüürmann G. 2004. Octanol/water partition coefficient of selected herbicides: Determination using shake-flask method and reversed-phase high-performance liquid chromatography. J Chem Eng Data 49:1639-1642.
57. Takács-Novák K, Avdeef A. 1996. Interlaboratory study of log P determination by shake-flask and potentiometric methods. J Pharm Biomed Anal 14:1405-1413.
58. Selvi B, Patel S, Savva M. 2008. Physicochemical characterization and membrane binding properties of camptothecin. J Pharm Sci 97:4379-4390.
59. Spelios M, Nedd S, Matsunaga N, Savva M. 2007. Effect of spacer attachment sites and pH-sensitive headgroup expansion on cationic lipid-mediated gene delivery of three novel myristoyl derivatives. Biophys Chem 129:137-147.
60. Ni N, Sanghvi T, Yalkowsky S. 2002. Solubilization and preformulation of carbendazim. Int J Pharm 244:99-104.
61. Wang SL, Lin SY, Hsieh TF, Chan SA. 2007. Thermal behavior and thermal decarboxylation of 10-hydroxycamptothecin in the solid state. J Pharm Biomed Anal 43:457-463.
62. Jae HS, Michael JS. 1998. Dimethyl sulfoxide as a mild oxidizing agent for porous silicon and its effect on photoluminescence. Inorg Chem 37:3355-3360.
63. Epstein WW, Sweat FW. 1967. Dimethyl sulfoxide oxidations. Chem Rev 67:247-260.
64. Freed AL, Strohmeyer HE, Mahjour M, Sadineni V, Reid DL, Kingsmill CA. 2008. pH control of nucleophilic/electrophilic oxidation. Int J Pharm 357:180-188.
65. Hartauer KJ, Arbuthnot GN, Baertschi SW, Johnson RA, Luke WD, Pearson NG, Rickard EC, Tingle CA, Tsang PK, Wiens RE. 2000. Influence of peroxide impurities in povidone and crospovidone on the stability of raloxifene hydrochloride in tablets: Identification and control of an oxidative degradation product. Pharm Dev Technol 5:303-310.
66. Crowley P, Martini L. 2001. Drug-excipient interactions. Pharm Technol Eur 13:26-34.
67. Waterman KC, Adami RC. 2005. Accelerated aging: Prediction of chemical stability of pharmaceuticals. Int J Pharm 293:101-125.
68. Fleury F, Kudelina I, Nabiev I. 1997. Interactions of lactone, carboxylate and self-aggregated forms of camptothecin with human and bovine serum albumins. FEBS Lett 406:151-156.
69. Nabiev I, Fleury F, Kudelina I, Pommier Y, Charton F, Riou JF, Alix AJ, Manfait M. 1998. Spectroscopic and biochemical characterisation of self-aggregates formed by antitumor drugs of the camptothecin family: Their possible role in the unique mode of drug action. Biochem Pharmacol 55:1163-1174.
70. Miyasaka T, Sawada S, Nokata K, Mutai M. 1985. Camptothecin-1-oxide derivatives. Patent US4513138 .
71. Savva M, Kunadharaju S. 2011. Thermodynamic analysis of enhanced solubility and stability of 10-hydroxycamptothecin in co-solvent and surfactant system. Glob J Phys Chem 2:22-33.
72. Alexandridis P, Holzwarth JF, Hatton AT. 1994. Micellization of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymers in aqueous solutions: Thermodynamics of copolymer association. Macromolecules 27:2414-2425.